Elad Kedar, Orasis CEO (Orasis)

Ora­sis Phar­ma­ceu­ti­cals snags $30M to see its pres­by­opia treat­ment through to PhI­II

Ora­sis Phar­ma­ceu­ti­cals is one of sev­er­al biotechs de­vel­op­ing mi­otic-based eye drops as a po­ten­tial al­ter­na­tive to read­ing glass­es — one drop, and no more squint­ing at text mes­sages. With the help of a $30 mil­lion Se­ries C, the Is­rael-based com­pa­ny has its sights set on Phase III.

“Read­ing glass­es are in­con­ve­nient, they are not aes­thet­i­cal­ly pleas­ing for many peo­ple, and then fi­nal­ly, they are al­so one of the very first signs of ag­ing,” said CEO Elad Kedar, who joined Ora­sis in 2015 short­ly af­ter the com­pa­ny was found­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.